Notice of AGM

ABZENA PLC

("Abzena", the "Company" or the "Group")

Notice of Annual General Meeting

27 August 2015

Cambridge, UK - Abzena plc (AIM: ABZA) announces that the Annual General Meeting (AGM), will be held at 10.30am on Monday 21 September 2015 at Babraham Research Campus, Babraham, Cambridge CB22 3AT.

A copy of the Notice and resolutions is available at http://abzena.com/financial-calendar.

For more information, please contact:

John Burt (Chief Executive Officer)

Julian Smith (Chief Financial Officer)

Abzena plc

Tel: +44 (0)1223 903498

Email: john.burt@abzena.com or julian.smith@abzena.com

Christopher Golden and Ivonne Cantu

Cenkos Securities (Nominated Adviser and Broker)

Tel: +44 (0)20 7397 8900

Mark Swallow

Citigate Dewe Rogerson (Corporate and Financial PR)

Tel: +44 (0)20 7638 9571

Email: abzena@citigatedr.co.uk

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups.

Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.

www.abzena.com